0000000000814984

AUTHOR

Ivana Resanovic

0000-0003-2742-7912

showing 2 related works from this author

High-Sensitivity C-Reactive Protein and Statin Initiation

2014

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

medicine.medical_specialtyStatinmedicine.drug_classInflammationBioinformaticsMultiple risk factorsRisk AssessmentPredictive Value of TestsRisk FactorsmedicineHumanscardiovascular diseasesDyslipidemiasInflammationbiologybusiness.industryPublic healthC-reactive protein3. Good healthCirculating biomarkersC-Reactive ProteinTreatment OutcomeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapybiology.proteinBiomarker (medicine)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

Anti-atherogenic Effects of 17β-Estradiol

2013

Estrogens are secreted primarily by the ovaries and placenta, by the testes in men and also produced by peripheral steroidogenic conversion. The 3 major naturally occurring estrogens are: 17β-estradiol (E2), estrone and estriol, of which E2 is the predominant and most active. The actions of E2 are mediated by at least 3 different receptors - the classical ERs (ERα and ERβ) and G-protein coupled receptor 30 (GPR30). E2 signaling in cardiomyocytes involves ERα- and ERβ-independent pathways, and treatment with the E2 receptor antagonists (Selective Estrogen Receptor Modulators- SERMs), which are agonists of GPR30, inhibits cardiac cell growth. Effects of E2 in preventing endothelial dysfunctio…

MaleSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyVascular smooth muscleEndotheliummedicine.drug_classEndocrinology Diabetes and MetabolismOvariectomyClinical BiochemistryInflammation030204 cardiovascular system & hematologyBiologyBiochemistry03 medical and health sciencesestrogen 17β-estradiol atherogenic factors atherosclerosis0302 clinical medicineEndocrinologyRisk FactorsInternal medicinemedicineAnimalsHumansEndothelial dysfunctionReceptorEstradiolBiochemistry (medical)Estrogen Replacement TherapyGeneral Medicinemedicine.diseaseAtherosclerosis3. Good healthmedicine.anatomical_structureEndocrinologySelective estrogen receptor modulatorEstrogen030220 oncology & carcinogenesisDiet AtherogenicFemalemedicine.symptomGPER
researchProduct